236. Pseudohypoparathyroidism Clinical trials / Disease details


Clinical trials : 3 Drugs : 3 - (DrugBank : 2) / Drug target genes : 18 - Drug target pathways : 23

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04551170
(ClinicalTrials.gov)
July 13, 20209/9/2020Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years OldPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1aDrug: Theophylline;Drug: PlaceboVanderbilt University Medical CenterNULLRecruiting2 Years12 YearsAll34Phase 2United States
2NCT02463409
(ClinicalTrials.gov)
June 201520/5/2015Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1aPseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: TheophyllineVanderbilt University Medical CenterMassachusetts General HospitalCompleted10 Years21 YearsAll6Phase 2United States
3NCT00497484
(ClinicalTrials.gov)
February 19955/7/2007Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Pseudohypoparathyroidism;Growth Hormone Deficiency, DwarfismDrug: recombinant human somatotropinUniversity of MilanEli Lilly and CompanyActive, not recruiting1 Year18 YearsBothN/AItaly